GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Cyclically Adjusted FCF per Share

InterMune (FRA:IUX) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is InterMune Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

InterMune's adjusted free cash flow per share for the three months ended in Jun. 2014 was €-0.396. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Jun. 2014.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-22), InterMune's current stock price is €58.06. InterMune's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2014 was €0.00. InterMune's Cyclically Adjusted Price-to-FCF of today is .


InterMune Cyclically Adjusted FCF per Share Historical Data

The historical data trend for InterMune's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune Cyclically Adjusted FCF per Share Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InterMune's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, InterMune's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where InterMune's Cyclically Adjusted Price-to-FCF falls into.



InterMune Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InterMune's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2014 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2014 (Change)*Current CPI (Jun. 2014)
=-0.396/100.5595*100.5595
=-0.396

Current CPI (Jun. 2014) = 100.5595.

InterMune Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200409 -0.123 80.121 -0.154
200412 -0.460 80.290 -0.576
200503 -0.392 81.555 -0.483
200506 -0.743 82.062 -0.910
200509 -0.466 83.876 -0.559
200512 -0.232 83.032 -0.281
200603 -0.782 84.298 -0.933
200606 -0.388 85.606 -0.456
200609 -0.280 85.606 -0.329
200612 0.839 85.142 0.991
200703 -0.129 86.640 -0.150
200706 -0.105 87.906 -0.120
200709 -0.416 87.964 -0.476
200712 -0.651 88.616 -0.739
200803 -0.400 90.090 -0.446
200806 -0.362 92.320 -0.394
200809 -0.053 92.307 -0.058
200812 -0.479 88.697 -0.543
200903 -0.948 89.744 -1.062
200906 -0.488 91.003 -0.539
200909 -0.093 91.120 -0.103
200912 -0.604 91.111 -0.667
201003 -0.513 91.821 -0.562
201006 -0.419 91.962 -0.458
201009 -0.241 92.162 -0.263
201012 1.386 92.474 1.507
201103 -0.625 94.283 -0.667
201106 -0.391 95.235 -0.413
201109 -0.400 95.727 -0.420
201112 -0.515 95.213 -0.544
201203 -0.564 96.783 -0.586
201206 -0.480 96.819 -0.499
201209 -0.515 97.633 -0.530
201212 -0.521 96.871 -0.541
201303 -0.510 98.209 -0.522
201306 -0.526 98.518 -0.537
201309 -0.468 98.790 -0.476
201312 -0.366 98.326 -0.374
201403 -0.453 99.695 -0.457
201406 -0.396 100.560 -0.396

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


InterMune  (FRA:IUX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


InterMune Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of InterMune's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Industry
Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines